Brief: Lidds Signs License Agreement For Prostate Cancer
16/05/2018 14:04
May 16 (Reuters) - Lidds AB LIDDS.ST :
* REG-LIDDS SIGNS LICENSE AGREEMENT FOR PROSTATE CANCER DRUG LIPROCA® DEPOT WITH MAJOR
CHINESE
PHARMA COMPANY
* HAS SIGNED A LICENSE AGREEMENT FOR LIPROCA® DEPOT WITH JIANGSU AMBITION MEDICAL
* LIDDS IS RECEIVING A SIGNING FEE EXCEEDING USD 1 MILLION FOLLOWED BY MILESTONE PAYMENTS
AND
ROYALTY
Source text for Eikon: ID:nGNE6H6ZZh
Further company coverage: LIDDS.ST
(Gdynia Newsroom)
((Gdynia.newsroom@thomsonreuters.com; +48 58 772 0920;))
Recent news on Lidds AB
See all newsBrief: Liquidator To Apply For Lidds To Be Declared Bankrupt
Brief: Lidds To Delist Shares From Nasdaq First North
Brief: Lidds Proposes Voluntary Liquidation And Delisting
Brief: Lidds Decides To Terminate Process Regarding Reverse Acquisition Of Proport Invest
Brief: Lidds Signs Agreement For Reverse Takeover Of Proport Invest